Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,325,280
  • Shares Outstanding, K 2,624,374
  • Annual Sales, $ 24,384 M
  • Annual Income, $ 1,335 M
  • 60-Month Beta 0.55
  • Price/Sales 5.82
  • Price/Cash Flow 17.08
  • Price/Book 11.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.44
  • Number of Estimates 4
  • High Estimate 0.46
  • Low Estimate 0.40
  • Prior Year 0.37
  • Growth Rate Est. (year over year) +18.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.95 +6.36%
on 06/12/20
55.19 -1.81%
on 06/23/20
+1.61 (+3.06%)
since 06/08/20
3-Month
43.50 +24.57%
on 04/09/20
57.44 -5.66%
on 05/21/20
+10.34 (+23.58%)
since 04/08/20
52-Week
36.15 +49.90%
on 03/16/20
57.44 -5.66%
on 05/21/20
+13.36 (+32.72%)
since 07/08/19

Most Recent Stories

More News
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer

AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.

AZN : 54.19 (+1.35%)
PFE : 33.80 (-0.68%)
MRK : 77.92 (-1.02%)
GSK : 40.73 (+0.87%)
Corvus Starts Immunotherapy Study on Coronavirus, Stock Rises

Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.

AZN : 54.19 (+1.35%)
RHHBY : 44.1200 (+1.17%)
AMGN : 251.59 (-0.62%)
CRVS : 5.37 (+8.38%)
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine

Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.

JNJ : 143.27 (+0.29%)
AZN : 54.19 (+1.35%)
NVAX : 98.30 (-5.99%)
EBS : 94.41 (+5.52%)
Immunomedics' Shares Rise on Positive Breast Cancer Drug Data

Shares of Immunomedics (IMMU) rise after it announces positive phase III data for its breast-cancer drug, Trodelvy.

AZN : 54.19 (+1.35%)
RHHBY : 44.1200 (+1.17%)
MRK : 77.92 (-1.02%)
IMMU : 41.55 (+0.95%)
Immunomedics' Shares Surge YTD on Cancer Drug Approval

Immunomedics' (IMMU) share price rises on the receipt of its first FDA approval for Trodelvy to treat metastatic triple-negative breast cancer patients.

AZN : 54.19 (+1.35%)
RHHBY : 44.1200 (+1.17%)
MRK : 77.92 (-1.02%)
IMMU : 41.55 (+0.95%)
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen

As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.

JNJ : 143.27 (+0.29%)
AZN : 54.19 (+1.35%)
PFE : 33.80 (-0.68%)
MRNA : 61.58 (+0.80%)
IBB : 140.81 (+0.54%)
XBI : 116.77 (+1.50%)
BBH : 168.10 (+0.48%)
FBT : 174.53 (+0.90%)
ARKG : 57.63 (+2.64%)
Peptide Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

, /PRNewswire/ -- The peptide therapeutics market is projected to grow with a CAGR of nearly 10.19% over the forecast period. The major factor attributing to the growth of the market is the growing incidence...

AMGN : 251.59 (-0.62%)
AZN : 54.19 (+1.35%)
BMY : 59.56 (-1.21%)
GSK : 40.73 (+0.87%)
PFE : 33.80 (-0.68%)
TKPYY : 16.5900 (-0.90%)
Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug

Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.

SNY : 51.52 (+0.17%)
AZN : 54.19 (+1.35%)
RDY : 52.26 (+1.57%)
RHHBY : 44.1200 (+1.17%)
Gilead's Coronavirus Drug Being Stocked by the US Government

Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.

ALXN : 108.00 (-3.97%)
AZN : 54.19 (+1.35%)
RHHBY : 44.1200 (+1.17%)
GILD : 75.61 (-1.06%)
BMY or AZN: Which Is the Better Value Stock Right Now?

BMY vs. AZN: Which Stock Is the Better Value Option?

BMY : 59.56 (-1.21%)
AZN : 54.19 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 55.26
1st Resistance Point 54.73
Last Price 54.19
1st Support Level 53.64
2nd Support Level 53.08

See More

52-Week High 57.44
Last Price 54.19
Fibonacci 61.8% 49.31
Fibonacci 50% 46.79
Fibonacci 38.2% 44.28
52-Week Low 36.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar